glp 1 competitive landscape GLP-1 Receptor Agonist Market Size, Share Obesity in the spotlight -

These medications mimic the hormone glucagon-like peptide-1, which helps regulate appetite and insulin secretion, offering a powerful tool for those struggling with obesity or weight-related health conditions

The platform emphasizes controlled dosing, continuity of care, and individualized treatment planning

Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition

Each batch undergoes heavy metal and endotoxin screening to ensure it is free from hidden contaminants